New drug could prevent eye cancer recurrence in High-Risk patients

NCT ID NCT06246149

Recruiting now Disease control Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether the drug tebentafusp can prevent uveal melanoma from coming back in high-risk patients after their initial treatment. About 290 people with a specific genetic marker (HLA-A*02:01) will either receive weekly infusions of tebentafusp or be observed without treatment. The goal is to see if the drug improves recurrence-free survival and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tebentafusp (a drug given weekly by IV infusion)
What this could lead to: If it works, this could reduce the chance of uveal melanoma coming back after initial treatment, potentially improving long-term survival.
What could go wrong: This is an early-stage test in a specific genetic group (HLA-A*02:01 positive). The drug may not prevent recurrence, and side effects from weekly infusions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEAL MELANOMA

Contacts and locations

Locations

Centre Antoine Lacassagne
RECRUITING

Nice, FR 06189, France
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
RECRUITING

Berlin, 12200, Germany
Cliniques Universitaires Saint-Luc
RECRUITING

Brussels, 1200, Belgium
East and North Hertfordshire NHS Trust - Mount Vernon Hospital
RECRUITING

Northwood, HA6 2RN, United Kingdom
Erasmus MC
RECRUITING

Rotterdam, NL 3015 GD, Netherlands
Hospital Clinico Universitario De Valladolid
RECRUITING

Valladolid, 47003, Spain
Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
RECRUITING

L'Hospitalet de Llobregat, 08908, Spain
Institut Curie - Hôpital de Paris
RECRUITING

Paris, 75248, France
Leiden University Medical Centre
RECRUITING

Leiden, 2300, Netherlands
Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology
RECRUITING

Warsaw, 02 781, Poland
Northwell Health -Center for Advanced Medicine
RECRUITING

Lake Success, New York, 11042, United States
Sahlgrenska Universitetssjukhuset
RECRUITING

Gothenburg, SE 413 45, Sweden
The Clatterbridge cancer Center NHS foundation Trust - Clatterbridge Cancer Center - Liverpool
RECRUITING

Liverpool, GB L7 8YA, United Kingdom
Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center
RECRUITING

Hamburg, 20246, Germany
Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik
RECRUITING

Heidelberg, DE 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.